ConductScience.org, home

Paper30953333

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.

Akizawa T and 4 others. Adv Ther, 2019. Cited by 79 papers, by iCite.

Cite this record

ConductScience Library. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. Papers, record 30953333. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30953333

Download JSON
Disease
anemia172 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
PubMed
Journal
Adv Ther
PubMed
Year
2019
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
79
iCite
Relative citation ratio, by iCite
3.64
iCite
Revised in PubMed
2022-01-11
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Akizawa TTadao
2Iwasaki MManabu
3Otsuka TTetsuro
4Reusch MMichael
5Misumi TToshihiro

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AnemiaMajor topic
Chronic DiseaseMajor topic
GlycineMajor topic
IsoquinolinesMajor topic
Renal Insufficiency, ChronicMajor topic
Adult
Aged
Double-Blind Method
Female
Humans
Japan
Male
Middle Aged
Placebo Effect

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01964196ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117557118Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).J Clin Invest2007https://conductscience.org/library/papers/17557118PubMed
226054543Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling.J Am Soc Nephrol2016https://conductscience.org/library/papers/26054543PubMed
317108343Correction of anemia with epoetin alfa in chronic kidney disease.N Engl J Med2006https://conductscience.org/library/papers/17108343PubMed
419218474Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).Clin J Am Soc Nephrol2009https://conductscience.org/library/papers/19218474PubMed
526494833Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.J Am Soc Nephrol2016https://conductscience.org/library/papers/26494833PubMed
630022586Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review.Ther Apher Dial2018https://conductscience.org/library/papers/30022586PubMed
727094610Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.Clin J Am Soc Nephrol2016https://conductscience.org/library/papers/27094610PubMed
828371815Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.Nephrol Dial Transplant2017https://conductscience.org/library/papers/28371815PubMed
926846333
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Am J Kidney Dis2016https://conductscience.org/library/papers/26846333PubMed
109718377The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.N Engl J Med1998https://conductscience.org/library/papers/9718377PubMed
1123291219Regulation of erythropoiesis by hypoxia-inducible factors.Blood Rev2013https://conductscience.org/library/papers/23291219PubMed
12206091782008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.Ther Apher Dial2010https://conductscience.org/library/papers/20609178PubMed
1319880844A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.N Engl J Med2009https://conductscience.org/library/papers/19880844PubMed
1416678659KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis2006https://conductscience.org/library/papers/16678659PubMed
1526238121Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.Nephrol Dial Transplant2015https://conductscience.org/library/papers/26238121PubMed
1619339088Revised equations for estimated GFR from serum creatinine in Japan.Am J Kidney Dis2009https://conductscience.org/library/papers/19339088PubMed
1715142852Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression.Am J Physiol Regul Integr Comp Physiol2004https://conductscience.org/library/papers/15142852PubMed
1823379486Hepcidin is a potential regulator of iron status in chronic kidney disease.Ther Apher Dial2013https://conductscience.org/library/papers/23379486PubMed
1920203166The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.Clin J Am Soc Nephrol2010https://conductscience.org/library/papers/20203166PubMed
2028118622Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.Am J Nephrol2017https://conductscience.org/library/papers/28118622PubMed

See all 21 referencesDownload CSV of references

Cited by60

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 79 citations.

PMIDTitleJournalYearIn PapersSource
42834713Acute Kidney Injury and Heart Failure Risk with Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors: A Network Meta-Analysis.Clin Pharmacol Ther2026https://conductscience.org/library/papers/42834713PubMed
42819330Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on transfusion and intravenous iron use in chronic kidney disease anemia: a systematic review and meta-analysis.Front Pharmacol2026https://conductscience.org/library/papers/42819330PubMed
42358369Thrombotic outcomes and mortality with roxadustat for anemia in chronic kidney disease: a systematic review and meta-analysis of randomized trials.Front Pharmacol2026https://conductscience.org/library/papers/42358369PubMed
41633330Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.Ren Fail2026https://conductscience.org/library/papers/41633330PubMed
41613326Frequency-reduction strategy of roxadustat in patients undergoing peritoneal dialysis: a multi-center retrospective cohort study.Front Med (Lausanne)2025https://conductscience.org/library/papers/41613326PubMed
41479171Safety Profile of Roxadustat in Anemic Patients: A Meta-Analysis of 21 RCTs.Medeni Med J2025https://conductscience.org/library/papers/41479171PubMed
41239296Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes.BMC Nephrol2025https://conductscience.org/library/papers/41239296PubMed
41155680Safety of Roxadustat in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41155680PubMed
40303227Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non-Dialysis-Dependent CKD-Associated Anemia.Kidney Int Rep2025https://conductscience.org/library/papers/40303227PubMed
40281613The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage.Cell Commun Signal2025https://conductscience.org/library/papers/40281613PubMed
39273415Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia.Int J Mol Sci2024https://conductscience.org/library/papers/39273415PubMed
39050745Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis.Front Pharmacol2024https://conductscience.org/library/papers/39050745PubMed
38664033[Effect of salvia miltiorrhiza combined with roxadustat on wound healing of full-thickness skin defects in diabetic rats and its mechanism].Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi2024https://conductscience.org/library/papers/38664033PubMed
38345037Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.Ren Fail2024https://conductscience.org/library/papers/38345037PubMed
38280066Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI).Adv Ther2024https://conductscience.org/library/papers/38280066PubMed
38279224Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury.Int J Mol Sci2024https://conductscience.org/library/papers/38279224PubMed
38098876Iron Supplements Concomitant within Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitors in the Treatment of Chronic Kidney Disease Anemia.Kidney Dis (Basel)2023https://conductscience.org/library/papers/38098876PubMed
37724564An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.Ren Fail2023https://conductscience.org/library/papers/37724564PubMed
37654676FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models.Front Physiol2023https://conductscience.org/library/papers/37654676PubMed
37562670Myeloid Hif2α is not essential to maintain systemic iron homeostasis.Exp Hematol2023https://conductscience.org/library/papers/37562670PubMed

See all 60 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CP1356PubTator's text mininghttps://conductscience.org/library/genes/1356NCBI Gene
EPO2056PubTator's text mininghttps://conductscience.org/library/genes/2056NCBI Gene
HAMP57817PubTator's text mininghttps://conductscience.org/library/genes/57817NCBI Gene
TF7018PubTator's text mininghttps://conductscience.org/library/genes/7018NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ROXADUSTATCHEMBL2338329Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2338329

Source ChEMBL

Download CSV of drugs

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
figshare10.6084/m9.figshare.7880417

Source figshare

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30953333

GET https://conductscience.org/api/papers/v1/30953333/references?page=2